Risk of kidney failure and death associated with target-dose (vs. below-target-dose) RAS inhibitors in HFrEF, HFmrEF and HFpEF: Spline-based reassessment of subgroup findings

By afschroeder • February 23, 2026

Raman VK, Vargas JD, Moore HJ, Wu WC, Patel SS, Zhang S, Morgan CJ, Lam PH, Heidenreich PA, Lu F, Ahmed AA, Fonarow GC, Ahmed A. Risk of kidney failure and death associated with target-dose (vs. below-target-dose) RAS inhibitors in HFrEF, HFmrEF and HFpEF: Spline-based reassessment of subgroup findings. Am J Med. 2026 Feb 21:S0002-9343(26)00079-3. doi: 10.1016/j.amjmed.2026.01.035. Epub ahead of print. PMID: 41724615.

Tags: Cardiology/Epi, Publications

Loss of ATP-Dependent Citrate Lyase Drives Left Ventricular Dysfunction by Metabolic Remodeling

Liu S, Gammon ST, Tan L, Gao Y, Kim K, Elbatreek MH, Arrieta A, Williamson IK, Salazar RL, Pham J, Davidian A, Khanna Neicheril R,[...]

Dashboard-Directed Intervention to Improve Guideline-Directed Heart Failure Therapy for Veterans

Sheng Q, Brownell NK, Hsu JJ, Chang DS, Fonarow GC, Ziaeian B. Dashboard-Directed Intervention to Improve Guideline-Directed Heart Failure Therapy for Veterans. JACC Adv. 2026[...]

An Immunologist’s Path Toward Advancing the Scientific Mission of the Prostate Cancer Foundation: Andrea Miyahira Talks with Johannes Czernin About the Role of the Prostate Cancer Foundation and Cancer Treatment

Miyahira A, Czernin J. An Immunologist's Path Toward Advancing the Scientific Mission of the Prostate Cancer Foundation: Andrea Miyahira Talks with Johannes Czernin About the[...]